MANNKIND CORP Contracts & Agreements
139 Contracts & Agreements
- Business Finance (68 contracts)
- Business Operations (20)
- Human Resources (8)
- Real Estate (3)
- Uncategorized (40)
- Offer Letter, dated March 25, 2024, between MannKind Corporation and Chris Prentiss (Filed With SEC on March 26, 2024)
- Description of Common Stock (Filed With SEC on February 27, 2024)
- Offer Letter, dated May 16, 2023, by and between MannKind Corporation and Sanjay Singh (Filed With SEC on February 27, 2024)
- Offer Letter, dated September 19, 2022, by and between MannKind Corporation and Burkhard Blank (Filed With SEC on February 27, 2024)
- License and Collaboration Agreement, dated September 3, 2018 by and between MannKind and United Therapeutics (Filed With SEC on February 27, 2024)
- MannKind Corporation 2018 Equity Incentive Plan Adopted by the Board of Directors: February 21, 2018 Approved by the Stockholders: May 16, 2018 Amended by the Board of Directors:... (Filed With SEC on August 7, 2023)
- MannKind Corporation 2004 Employee Stock Purchase Plan Adopted by the Board of Directors March 23, 2004 Approved by Stockholders March 23, 2004 Amended by the Board of Directors... (Filed With SEC on August 7, 2023)
- Offer Letter, dated March 21, 2023, by and between MannKind Corporation and Lauren M. Sabella (Filed With SEC on March 27, 2023)
- Amendment No. 8 to Credit and Security Agreement, dated November 3, 2021, by and among MannKind Corporation, MannKind LLC, QrumPharma, Inc., and MidCap Financial Trust (Filed With SEC on February 23, 2023)
- Amendment No. 9 to Credit and Security Agreement, dated November 8, 2021, by and among MannKind Corporation, MannKind LLC, QrumPharma, Inc., and MidCap Financial Trust (Filed With SEC on February 23, 2023)
- Second Amendment to Commercial Supply Agreement, dated June 15, 2022, by and between MannKind Corporation and United Therapeutics Corporation (Filed With SEC on February 23, 2023)
- Third Amendment to Commercial Supply Agreement, dated August 31, 2022, by and between MannKind Corporation and United Therapeutics Corporation (Filed With SEC on February 23, 2023)
- Fourth Amendment to Commercial Supply Agreement, dated December 22, 2022, by and between MannKind Corporation and United Therapeutics Corporation (Filed With SEC on February 23, 2023)
- Office Lease, dated May 10, 2017, by and between Valeritas, Inc. and RFP Lincoln 293 LLC (Filed With SEC on February 23, 2023)
- First Amendment to Office Lease, date February 11, 2019, by and between Valeritas, Inc. and BRP 293 Equity Partners, LLC (Filed With SEC on February 23, 2023)
- Amendment No. 10 to the Credit and Security Agreement, dated August 29, 2022, by and among MannKind Corporation, MannKind LLC, QrumPharma, Inc., and MidCap Financial Trust (Filed With SEC on November 8, 2022)
- Commercial Supply Agreement, dated August 12, 2021, by and between MannKind Corporation and United Therapeutics Corporation (Filed With SEC on November 9, 2021)
- First Amendment to Commercial Supply Agreement, dated October 16, 2021, by and between MannKind Corporation and United Therapeutics Corporation (Filed With SEC on November 9, 2021)
- Purchase and Sale Agreement, dated September 23, 2021, by and between MannKind Corporation and 1 Casper, LLC (Filed With SEC on November 9, 2021)
- Indenture, dated as of March 4, 2021, by and between MannKind Corporation and U.S. Bank National Association, as Trustee (Filed With SEC on March 5, 2021)
- Description of Common Stock (Filed With SEC on February 25, 2021)
- Offer Letter, dated May 7, 2020 by and between MannKind and Alejandro Galindo (Filed With SEC on February 25, 2021)
- Offer Letter, dated August 11, 2003, by and between MannKind and Joseph Kocinsky (Filed With SEC on February 25, 2021)
- Supply Agreement, dated as of July 31, 2014, by and between MannKind and Amphastar France Pharmaceuticals S.A.S (Filed With SEC on February 25, 2021)
- Purchase Agreement, dated December 7, 2020 by and among the Company, the Acquired Company, the Sellers and the Securityholders Representative (Filed With SEC on December 7, 2020)
- Amendment No. 4 to Credit and Security Agreement, dated December 7, 2020 by and among the Company, MannKind LLC and MidCap Financial Trust (Filed With SEC on December 7, 2020)
- MannKind Corporation 2018 Equity Incentive Plan, as amended (Filed With SEC on August 5, 2020)
- Description of Common Stock (Filed With SEC on February 25, 2020)
- Amendment to Common Stock Purchase Warrant, dated December 22, 2019, by and between MannKind Corporation and CVI Investments, Inc (Filed With SEC on December 23, 2019)
- Form of Warrant to Purchase Stock (Filed With SEC on August 7, 2019)
- Promissory Note due June 30, 2020 made by MannKind Corporation in favor of Bruce & Co., Inc., dated August 6, 2019 (Filed With SEC on August 7, 2019)
- Promissory Note due December 31, 2020 made by MannKind Corporation in favor of Bruce & Co., Inc., dated August 6, 2019 (Filed With SEC on August 7, 2019)
- Convertible Promissory Note made by MannKind Corporation in favor of The Mann Group LLC, dated August 6, 2019 (Filed With SEC on August 7, 2019)
- Promissory Note made by MannKind Corporation in favor of The Mann Group LLC, dated August 6, 2019 (Filed With SEC on August 7, 2019)
- Form of 5.75% Convertible Senior Subordinated Exchange Notes Due 2024 (included in Exhibit 4.3 as Exhibit A thereto) (Filed With SEC on August 7, 2019)
- Non-Employee Director Compensation Program (Filed With SEC on February 26, 2019)
- Fourth Amendment to Supply Agreement, dated December 24, 2018, by and between MannKind and Amphastar Pharmaceuticals, Inc (Filed With SEC on February 26, 2019)
- Underwriting Agreement, dated December 19, 2018, by and between MannKind Corporation and Leerink Partners LLC, as representative of the several underwriters named therein (Filed With SEC on December 21, 2018)
- Form of Common Stock Purchase Warrant (Filed With SEC on December 21, 2018)
- License and Collaboration Agreement, dated September 3, 2018 by and between MannKind and United Therapeutics Corporation (Filed With SEC on November 1, 2018)
- Research Agreement, dated September 3, 2018 by and between MannKind and United Therapeutics Corporation (Filed With SEC on November 1, 2018)
- Third Amendment to Supply Agreement, dated April 11, 2018, by and between MannKind and Amphastar Pharmaceuticals, Inc (Filed With SEC on May 9, 2018)
- Form of Common Stock Purchase Warrant (Filed With SEC on April 6, 2018)
- Offer Letter dated February 17, 2017, by and between MannKind and Courtney Barton (Filed With SEC on February 27, 2018)
- Offer Letter dated June 28, 2017, by and between MannKind and Patrick McCauley (Filed With SEC on February 27, 2018)
- Offer Letter dated February 2, 2018, by and between MannKind and David Kendall (Filed With SEC on February 27, 2018)
- Non-Employee Director Compensation Program (Filed With SEC on February 27, 2018)
- Controlled Equity OfferingSM Sales Agreement, by and between MannKind and Cantor Fitzgerald & Co., dated February 27, 2018 (Filed With SEC on February 27, 2018)
- Indenture, by and between the Company and U.S. Bank National Association, dated October 30, 2017 (Filed With SEC on October 30, 2017)
- OFFICE LEASE BETWEEN RUSSELL RANCH ROAD II LLC, aDelaware limited liability company, AS LANDLORD AND MANNKIND CORPORATION, a Delaware corporation AS TENANT OFFICE LEASE (Filed With SEC on August 7, 2017)
- SETTLEMENT AGREEMENT (Filed With SEC on March 16, 2017)
- FIRST AMENDMENT TO SUPPLY AGREEMENT (Filed With SEC on March 16, 2017)
- SECONDAMENDMENT TO SUPPLY AGREEMENT (Filed With SEC on March 16, 2017)
- FIRST AMENDMENT TO AGREEMENT OF PURCHASE AND SALE AND JOINT ESCROW INSTRUCTIONS (Filed With SEC on March 16, 2017)
- MANNKIND CORPORATION 2013 EQUITY INCENTIVE PLAN, AS AMENDED ADOPTED BY THE BOARD OFDIRECTORS: MARCH 7, 2013 APPROVED BY THESTOCKHOLDERS: MAY 23, 2013 AMENDED BYTHE BOARD: APRIL 4,... (Filed With SEC on August 9, 2016)
- FORM OF SERIES ACOMMON STOCK PURCHASE WARRANT MANNKIND CORPORATION (Filed With SEC on May 10, 2016)
- SERIES B COMMON STOCK PURCHASE WARRANT MANNKIND CORPORATION (Filed With SEC on May 10, 2016)
- MANNKIND CORPORATION WARRANT TO PURCHASE COMMON STOCK (Filed With SEC on March 15, 2016)
- EXHIBIT A SEPARATION DATE RELEASE (To be signed on or within 21 days after the Separation Date.) (Filed With SEC on March 15, 2016)
- EXHIBIT A SEPARATION DATE RELEASE (Tobe signed on or within 45 days after the Separation Date.) (Filed With SEC on March 15, 2016)
- MANNKIND CORPORATION AND U.S. BANK NATIONAL ASSOCIATION as Trustee INDENTURE Dated as of August 14, 2015 5.75% Convertible Senior Subordinated Exchange Notes due 2015 TABLE OF... (Filed With SEC on August 18, 2015)
- A-1 MANNKIND CORPORATION 5.75% Convertible Senior Subordinated Exchange Notes due 2015 (Filed With SEC on August 18, 2015)
- MANNKIND CORPORATION AND WELLS FARGO BANK, NATIONAL ASSOCIATION as Trustee INDENTURE Dated as of August 10, 2015 5.75% Convertible Senior Subordinated Exchange Notes due 2018... (Filed With SEC on August 10, 2015)
- MANNKIND CORPORATION 5.75%Convertible Senior Subordinated Exchange Notes due 2018 (Filed With SEC on August 10, 2015)
- SECOND AMENDMENT TO FACILITY AGREEMENT (Filed With SEC on November 10, 2014)
- LICENSE AND COLLABORATION AGREEMENT (Filed With SEC on November 10, 2014)
- SUPPLY AGREEMENT (Filed With SEC on November 10, 2014)
- SUPPLY AGREEMENT (Filed With SEC on November 10, 2014)
- TRANCHE B SENIOR SECURED NOTE (Filed With SEC on May 12, 2014)
- AMENDED AND RESTATED SENIOR SECURED CONVERTIBLE NOTE (Filed With SEC on March 3, 2014)
- MANNKIND CORPORATION Common Stock (par value $0.01 pershare) At-The-Market Issuance Sales Agreement (Filed With SEC on March 3, 2014)
- MANNKIND CORPORATION Common Stock (par value $0.01 pershare) At-The-Market Issuance Sales Agreement (Filed With SEC on March 3, 2014)
- FIRST AMENDMENT TO FACILITY AGREEMENT AND REGISTRATION RIGHTS AGREEMENT (Filed With SEC on March 3, 2014)
- MANNKIND CORPORATION Boardof Directors Compensation Program for Non-Employee Directors Updated March 25, 2013 (Filed With SEC on August 9, 2013)
- MANNKIND CORPORATION WARRANT TO PURCHASE COMMON STOCK (Filed With SEC on March 18, 2013)
- MANNKIND CORPORATION Common Stock (par value $0.01 per share) At-The-Market Issuance Sales Agreement (Filed With SEC on March 18, 2013)
- MANNKIND CORPORATION Common Stock (par value $0.01 per share) At-The-Market Issuance Sales Agreement (Filed With SEC on March 18, 2013)
- 40,000,000 Shares of Common Stock ($0.01 par valueper Share) and Warrants to Purchase up to 30,000,000 Shares of Common Stock MannKindCorporation UNDERWRITING AGREEMENT (Filed With SEC on October 19, 2012)
- MANNKIND CORPORATION WARRANT TO PURCHASE COMMON STOCK (Filed With SEC on October 19, 2012)
- MANNKIND CORPORATION COMMON STOCK AND WARRANT PURCHASE AGREEMENT (Filed With SEC on October 19, 2012)
- AMENDED AND RESTATED PROMISSORY NOTE (Filed With SEC on October 19, 2012)
- AMENDMENT TO $350 MILLION AMENDED AND RESTATED PROMISSORY NOTE (Filed With SEC on July 3, 2012)
- AMENDMENT TO $350 MILLION AMENDED AND RESTATED PROMISSORY NOTE (Filed With SEC on May 10, 2012)
- 31,250,000 Units Each Unit Consisting of One Share of Common Stock ($0.01 par value per Share) and A Warrant to Purchase 0.6 of a Share of Common Stock MannKind Corporation... (Filed With SEC on February 6, 2012)
- MANNKIND CORPORATION WARRANT TO PURCHASE COMMON STOCK (Filed With SEC on February 6, 2012)
- MANNKIND CORPORATION COMMON STOCK PURCHASE AGREEMENT (Filed With SEC on February 6, 2012)
- AMENDMENT TO $350 MILLION AMENDED AND RESTATED PROMISSORY NOTE (Filed With SEC on January 20, 2012)
- EX-101 INSTANCE DOCUMENT (Filed With SEC on August 4, 2011)
- EX-101 INSTANCE DOCUMENT (Filed With SEC on August 4, 2011)
- MANNKIND CORPORATION (A Delaware corporation) 9,000,000 Shares of Common Stock UNDERWRITING AGREEMENT (Filed With SEC on August 24, 2010)
- MANNKIND CORPORATION AND WELLS FARGO BANK, NATIONAL ASSOCIATION as Trustee INDENTURE Dated as of August 24, 2010 5.75% Convertible Senior Notes due 2015 (Filed With SEC on August 24, 2010)
- [FORM OF FACE OF NOTE] [INCLUDE IF A GLOBAL NOTE] (Filed With SEC on August 24, 2010)
- COMMON STOCK PURCHASE AGREEMENT (Filed With SEC on August 11, 2010)
- OMNI CAPITAL CORPORATION 119 West 72nd Street Suite 283 33 West Main Street POB 390New York, NY 10023 Oyster Bay, NY 11771 Mr. Matthew J. Pfeffer August 10, 2010Chief Financial... (Filed With SEC on August 11, 2010)
- MANNKIND CORPORATION COMMON STOCK PURCHASE AGREEMENT (Filed With SEC on August 11, 2010)
- AMENDED AND RESTATED PROMISSORY NOTE $350,000,000 Dated August 10, 2010 Valencia, California (Filed With SEC on August 11, 2010)
- 7,400,000 Shares (Filed With SEC on August 10, 2009)
- Current assets (Filed With SEC on May 4, 2009)
- Current assets (Filed With SEC on May 4, 2009)
- the risk of severe hypoglycemia, which is abnormally low levels of blood glucose that result from excessive insulin administration. Hypoglycemia can result in loss of mental... (Filed With SEC on February 27, 2009)
- the risk of severe hypoglycemia, which is abnormally low levels of blood glucose that result from excessive insulin administration. Hypoglycemia can result in loss of mental... (Filed With SEC on March 14, 2008)
- Current assets (Filed With SEC on August 9, 2007)
- PROMISSORY NOTE $150,000,000 August 1, 2007 Valencia, California (Filed With SEC on August 3, 2007)
- MANNKIND CORPORATION Issuer And WELLS FARGO BANK, N.A. Trustee FIRST SUPPLEMENTAL INDENTURE Dated as of December 12, 2006 (Filed With SEC on December 12, 2006)
- MANNKIND CORPORATION (Filed With SEC on December 8, 2006)
- MANNKIND CORPORATION (Filed With SEC on December 8, 2006)
- Current assets (Filed With SEC on November 2, 2006)
- Current assets (Filed With SEC on August 3, 2006)
- MannKind Corporation Officers Incentive Program (Filed With SEC on March 16, 2006)
- MannKind Corporation 2004 Non-Employee Directors Stock Option Plan Adopted March 23, 2004 Approved by Stockholders March 23, 2004 Effective Date: August 2, 2004 (Filed With SEC on March 16, 2006)
- Supply Agreement dated December 31, 2004 between MannKind Corporation and Vaupell, Inc (Filed With SEC on February 23, 2005)
- Pro forma (Filed With SEC on September 3, 2004)
- Consent of Deloitte & Touche LLP (Filed With SEC on July 27, 2004)
- 2004 Equity Incentive & Stock Option Agreement (Filed With SEC on July 26, 2004)
- 2004 Non-Employee Directors' Stock Option Plan (Filed With SEC on July 26, 2004)
- 2004 Employee Stock Purchase & Offering Document (Filed With SEC on July 26, 2004)
- Approximates natural first-phase insulin release spike. Typically, regular insulin delivered by subcutaneous injection results in peak insulin levels in about 120 to 180 minutes.... (Filed With SEC on July 6, 2004)
- Approximates natural first-phase insulin release spike. Typically, regular insulin delivered by subcutaneous injection results in peak insulin levels in about 120 to 180 minutes.... (Filed With SEC on July 6, 2004)
- Approximates natural first-phase insulin release spike. Typically, regular insulin delivered by subcutaneous injection results in peak insulin levels in about 120 to 180 minutes.... (Filed With SEC on July 6, 2004)
- Approximates natural first-phase insulin release spike. Typically, regular insulin delivered by subcutaneous injection results in peak insulin levels in about 120 to 180 minutes.... (Filed With SEC on July 6, 2004)
- Approximates natural first-phase insulin release spike. Typically, regular insulin delivered by subcutaneous injection results in peak insulin levels in about 120 to 180 minutes.... (Filed With SEC on July 6, 2004)
- Approximates natural first-phase insulin release spike. Typically, regular insulin delivered by subcutaneous injection results in peak insulin levels in about 120 to 180 minutes.... (Filed With SEC on July 6, 2004)
- Technosphere Insulin approximation (Filed With SEC on April 30, 2004)
- Technosphere Insulin approximation (Filed With SEC on April 30, 2004)
- Technosphere Insulin approximation (Filed With SEC on April 30, 2004)
- Technosphere Insulin approximation (Filed With SEC on April 30, 2004)
- Technosphere Insulin approximation (Filed With SEC on April 30, 2004)
- Technosphere Insulin approximation (Filed With SEC on April 30, 2004)
- Technosphere Insulin approximation (Filed With SEC on April 30, 2004)
- Technosphere Insulin approximation (Filed With SEC on April 30, 2004)
- Technosphere Insulin approximation (Filed With SEC on April 30, 2004)
- Technosphere Insulin approximation (Filed With SEC on April 30, 2004)
- Technosphere Insulin approximation (Filed With SEC on April 30, 2004)
- Technosphere Insulin approximation (Filed With SEC on April 30, 2004)
- Technosphere Insulin approximation (Filed With SEC on April 30, 2004)
- Technosphere Insulin approximation (Filed With SEC on April 30, 2004)
- Technosphere Insulin approximation (Filed With SEC on April 30, 2004)
- Technosphere Insulin approximation (Filed With SEC on April 30, 2004)
- Technosphere Insulin approximation (Filed With SEC on April 30, 2004)